Headlines about Aduro BioTech (NASDAQ:ADRO) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aduro BioTech earned a news impact score of 0.24 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.1843466417878 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news headlines that may have impacted Accern’s analysis:
- Monthly Up Look: Aduro BioTech, Inc. (ADRO) stock moves 38.89% – The Stocks News (press release) (thestocksnews.com)
- Aduro BioTech Inc (ADRO) Expected to Post Quarterly Sales of $4.60 Million (americanbankingnews.com)
- Aduro BioTech (ADRO) Stock Rating Upgraded by BidaskClub (americanbankingnews.com)
- Brokerages Anticipate Aduro BioTech Inc (ADRO) to Announce -$0.31 EPS (americanbankingnews.com)
- Key events next week – healthcare (continued #4) – Seeking Alpha (seekingalpha.com)
Aduro BioTech (NASDAQ ADRO) traded down $0.04 during trading hours on Tuesday, reaching $9.01. 13,398 shares of the company’s stock were exchanged, compared to its average volume of 544,064. The firm has a market capitalization of $708.81, a PE ratio of -7.14 and a beta of 2.75. Aduro BioTech has a 52 week low of $5.82 and a 52 week high of $14.05.
In other Aduro BioTech news, insider Stephen T. Isaacs sold 7,949 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $7.95, for a total transaction of $63,194.55. Following the completion of the transaction, the insider now directly owns 213,695 shares in the company, valued at $1,698,875.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Elsas Andrea Van sold 6,874 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.48, for a total transaction of $44,543.52. Following the transaction, the insider now owns 216,669 shares of the company’s stock, valued at $1,404,015.12. The disclosure for this sale can be found here. Insiders have sold 174,981 shares of company stock valued at $1,423,682 over the last 90 days. 6.60% of the stock is currently owned by company insiders.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.